MPTP hydrochloride
(Synonyms: 1-甲基-4-苯基-1,2,3,6-四氢吡啶盐酸盐,MPTP) 目录号 : GC11097
MPTP（1-甲基-4-苯基-1,2,3,6-四氢吡啶）是一种神经毒性物质，它是MPP+的前体，对多巴胺能神经元有毒，并导致帕金森病。
Cas No.:23007-85-4
Sample solution is provided at 25 µL, 10mM.
MPTP (1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine) is a neurotoxic agent that is a precusor of MPP+ which is toxic to dopaminergic neurons and causes Parkinsonism. It is commonly used in research to induce Parkinson′s disease models in primates. The MPTP neurotoxicity in humans is irreversible and the consequential clinical and neurochemical features closely resemble those of the idiopathic Parkinson’s disease.[1]
In vivo analysis demonstrated that systemic MPTP treatments could lead to parkinsonian. Animals developed moderate-to-severe parkinsonian signs, including a marked loss of spontaneous movements (akinesia), muscular rigidity, and severe postural instability.[2] Most of the MPTP and metabolites were excreted in the urine within the first hour after treatment. MPTP metabolite found in the urine during the first hour after treatment is MPTP N-oxide. However, MPTP N-oxide and MPP+ may cause DA depletion only if injected directly into the neostriatum.[1]
References:
[1]. Lau YS, et al. MPTP treatment in mice does not transmit and cause Parkinsonian neurotoxicity in non-treated cagemates through close contact. Neurosci Res. 2005 Aug;52(4):371-8.
[2].Bergman H, et al. Physiology of MPTP tremor. Mov Disord. 1998;13 Suppl 3:29-34.
MPTP（1-甲基-4-苯基-1,2,3,6-四氢吡啶）是一种神经毒性物质，它是MPP+的前体，对多巴胺能神经元有毒，并导致帕金森病。在研究中常用于诱导灵长类动物的帕金森病模型。人类中的MPTP神经毒性是不可逆转的，其临床和神经化学特征与特发性帕金森病非常相似。
实验表明，全身性的MPTP处理会导致帕金森病。动物出现了中度到严重的帕金森症状，包括自发运动（静止）、肌肉僵硬和严重的姿势不稳定。大部分MPTP及其代谢产物在治疗后第一小时内通过尿液排出体外。在治疗后第一小时内尿液中发现的MPTP代谢产物是MPTP N-氧化物。然而，只有将MPTP N-氧化物和MPP+直接注入新纹状体才可能导致多巴胺耗竭。[1]
| Animal experiment [2]: | |
|
Animal models |
10-week-old (25–28 g), male, C57BL/6 mice |
|
Preparation Method |
The MPTP-treated and exposed mice received a conventional, single dose of MPTP hydrochloride for 5 consecutive days and were kept in single cages in a separate room (T/E group). |
|
Dosage form |
30 mg/kg/day, s.c. |
|
Applications |
MPTP hydrochloride has been widely used for inducing Parkinsonism in a variety of laboratory animals, especially in mice. MPTP could cause substantial loss of TH immunoreactivity in the SNpc as well as a significant diminution of TH protein level in the substantia nigra and striatum. |
|
References: [1]. Lau YS, et al. MPTP treatment in mice does not transmit and cause Parkinsonian neurotoxicity in non-treated cagemates through close contact. Neurosci Res. 2005 Aug;52(4):371-8. |
|
| Cas No. | 23007-85-4 | SDF | |
| 别名 | 1-甲基-4-苯基-1,2,3,6-四氢吡啶盐酸盐,MPTP | ||
| 化学名 | 1-methyl-4-phenyl-3,6-dihydro-2H-pyridine;hydrochloride | ||
| Canonical SMILES | CN1CCC(=CC1)C2=CC=CC=C2.Cl | ||
| 分子式 | C12H16ClN | 分子量 | 209.72 |
| 溶解度 | ≥ 20.52 mg/mL in DMSO with ultrasonic and warming, ≥ 25.45 mg/mL in EtOH with ultrasonic and warming, ≥ 21 mg/mL in Water | 储存条件 | Store at -20°C |
| General tips | 请根据产品在不同溶剂中的溶解度选择合适的溶剂配制储备液；一旦配成溶液，请分装保存，避免反复冻融造成的产品失效。 储备液的保存方式和期限：-80°C 储存时，请在 6 个月内使用，-20°C 储存时，请在 1 个月内使用。 为了提高溶解度，请将管子加热至37℃，然后在超声波浴中震荡一段时间。 |
||
| Shipping Condition | 评估样品解决方案：配备蓝冰进行发货。所有其他可用尺寸：配备RT，或根据请求配备蓝冰。 | ||
| 制备储备液 | |||
 |
1 mg | 5 mg | 10 mg |
| 1 mM | 4.7683 mL | 23.8413 mL | 47.6826 mL |
| 5 mM | 0.9537 mL | 4.7683 mL | 9.5365 mL |
| 10 mM | 0.4768 mL | 2.3841 mL | 4.7683 mL |
| 第一步：请输入基本实验信息（考虑到实验过程中的损耗，建议多配一只动物的药量） | ||||||||||
| 给药剂量 | mg/kg |  |
动物平均体重 | g | |
每只动物给药体积 | ul | |
动物数量 | 只 |
| 第二步：请输入动物体内配方组成（配方适用于不溶于水的药物；不同批次药物配方比例不同，请联系GLPBIO为您提供正确的澄清溶液配方） | ||||||||||
| % DMSO % % Tween 80 % saline | ||||||||||
| 计算重置 | ||||||||||
计算结果:
工作液浓度： mg/ml；
DMSO母液配制方法： mg 药物溶于 μL DMSO溶液（母液浓度 mg/mL，
体内配方配制方法：取 μL DMSO母液，加入 μL PEG300，混匀澄清后加入μL Tween 80，混匀澄清后加入 μL saline，混匀澄清。
1. 首先保证母液是澄清的；
2.
一定要按照顺序依次将溶剂加入，进行下一步操作之前必须保证上一步操作得到的是澄清的溶液，可采用涡旋、超声或水浴加热等物理方法助溶。
3. 以上所有助溶剂都可在 GlpBio 网站选购。
Quality Control & SDS
- View current batch:
- Purity: >98.00%
- COA (Certificate Of Analysis)
- SDS (Safety Data Sheet)
- Datasheet
